Views & Analysis Kick-starting innovation in Glioblastoma Can risk-sharing and real-world evidence can provide traction in treating the brain cancer Glioblastoma?
Views & Analysis Addressing market access obstacles for rare bleeding disorde... Scrutiniseing the market access situation for people with rare bleeding disorders.
Views & Analysis Navigating the barriers to successful market access The steps required for successful market access.
Views & Analysis Keeping ahead of the curve Jon Williams, President of Evidera, is well-placed to offer his views on the issues impacting access to therapies.
Views & Analysis Pharma 2022: big pharma will remain a constant Pharma 2022: big pharma to maintain its position, ready to pounce on any newcomer that shows promise.
Views & Analysis Get real: virtual reality for healthcare comes of age After a few false dawns over the years, has virtual reality’s time come?
News Court sides with EU on decision to revoke Ocaliva's license Advanz Pharma's bid to keep its Ocaliva treatment for rare liver disease primary biliary cholangitis (PBC) on the EU market has ended in failure
Sales & Marketing Coming soon: The Life Sciences Industry Report 2025 – insigh... Prepare for 2025 with pharmaphorum’s Life Sciences Report, featuring expert insights on AI in drug development, gene therapy, and top industry trends
